STERIS plc
STEHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, STERIS plc focuses on Medical Devices services and products. STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. With a market capitalization of $21.30B, it sits in large-cap territory. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences.
Market Cap
$21.30B
Beta
0.91
P/E (TTM)
26.70
P/E (Fwd)
17.84
EPS (TTM)
$8.18
EPS (Fwd)
$12.25
ROE
11.4%
ROA
6.8%
Cash
$482.3M
Total Debt
$2.04B
Free CF
$798.9M
52W Change
-7.9%
Annual Financials
Cash vs Debt
Where STE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, STE finished 2.74% above its 150-day moving average ($224.20) and 0.93% below its 200-day moving average ($232.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STE overbought or oversold?
At the September 3, 2026 close, STE's RSI(14) was 39.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
STERIS plc carries $2.04B in total debt against $482.3M in cash reserves — debt is roughly 4.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $798.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $4.54B (2023) to $5.94B (2026), reflecting a 31% increase over the period.
Investors considering STERIS plc should weigh the typical risks associated with STE's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STE.